Ruxolitinib (free base)

Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro.

Price Not Available 25 mg Ruxolitinib (free base) Supplier Page
Catalog Number AG-CR1-3624-M025
Alternative Name(s) INCB018424; INC 424
Research Area Apoptosis, Autophagy, Biochemicals, Cancer, Immunology, Inflammation
Molecular Formula C17H18N6
CAS# 941678-49-5
Purity >98%
Inchi InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
Inchi Key HFNKQEVNSGCOJV-OAHLLOKOSA-N
SMILES N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
Size 25 mg
Supplier Page http://www.adipogen.com/ag-cr1-3624/ruxolitinib.html